Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
| LHLONGEVITY | SCBRMGHC | |
|---|---|---|
| Held by both | ||
| 4.51% | 9.70% | |
| 3.27% | 4.98% | |
| 4.78% | 2.37% | |
| Only in LHLONGEVITY | ||
| 5.42% | N/A | |
| 4.67% | N/A | |
| 3.64% | N/A | |
| 3.41% | N/A | |
| Only in SCBRMGHC | ||
| N/A | 7.85% | |
| N/A | 4.31% | |
| N/A | 3.74% | |
| N/A | 3.38% | |
26 Mar 2026 → 2 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| SCBRMGHC | +17.19% | 17.61% | 0.98 |
| LHLONGEVITY | +11.21% | 22.33% | 0.50 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | LHLONGEVITY | SCBRMGHC |
|---|---|---|
Fund details | ||
| Fund size | 75.68 million | 2,408 million |
| Inception date | 27 Mar 2026 | 6 Nov 2015 |
| Master fund | Tema Oncology ETF | Janus Henderson Global Life Sciences Fund |
| Dividend policy | Does not pay | Does not pay |
Risk and currency hedging | ||
| Risk level | 7 | 7 |
| Hedging policy | Hedged at the manager's discretion | Almost fully hedged |
| Share hedged | 79.91% | 100.58% |
Minimum purchase and redemption | ||
| First purchase | 1,000 THB | 1,000 THB |
| Subsequent purchase | 100 THB | 1,000 THB |
| Redemption (amount) | No minimum | 1,000 THB |
| Redemption (units) | No minimum | No minimum |
| Balance (amount) | 100 THB | 1,000 THB |
| Balance (units) | No minimum | No minimum |
Order cut-off and redemption payment | ||
| Buy before | 15:30 | 15:30 |
| Redeem before | 15:30 | 15:30 |
| Redemption paid | T+2 | T+5 |